Literature DB >> 12477458

Pneumocystis carinii pneumonia in a patient with stage IV ovarian cancer.

Minoru Watanabe1, Yoichi Aoki, Hitoshi Kurata, Kenichi Tanaka.   

Abstract

BACKGROUND: Immunocompromised persons are considered to be at risk of developing Pneumocystis carinii pneumonia, although the incidence of this condition is much lower compared to the human immunodeficiency virus-positive group. It is important to identify specific individuals at high clinical risk to guide the chemoprophylaxis of P. carinii pneumonia. CASE: A 42-year-old female with stage IV ovarian cancer developed P. carinii pneumonia during radiotherapy for brain metastasis while receiving 7 weeks of prednisolone. Four weeks before the diagnosis, her lymphocyte count dropped to 350/microl. She was treated with pentamidine followed by trimethoprim-sulfamethoxazole with the support of mechanical ventilation. The patient could then be weaned from mechanical ventilatory support. However, she was not able to receive any additional therapy for her ovarian cancer.
CONCLUSION: Cancer patients who receive corticosteroids during chemotherapy or radiation therapy are at risk of developing P. carinii pneumonia and should receive P. carinii pneumonia prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477458     DOI: 10.1006/gyno.2002.6821

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Unsuspected Pneumocystis pneumonia in an HIV-seronegative patient with untreated lung cancer: circa case report.

Authors:  Cai Chuang; Xie Zhanhong; Gu Yinyin; Zeng Qingsi; Zhong Shuqing; Zhong Nanshan
Journal:  J Med Case Rep       Date:  2007-10-28

2.  Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy.

Authors:  Daisuke Himeji; Gen-Ichi Tanaka; Ritsuya Shiiba; Ryoichi Matsumoto; Kazuhiro Takamura; Hirotaka Morishita; Shuichi Taniguchi; Sayaka Moriguchi; Kousuke Marutsuka
Journal:  Intern Med       Date:  2021-07-10       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.